The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma
Abstract Background A high proportion of patients with advanced stages of medullary thyroid carcinoma (MTC) present with liver metastasis metastases. The aim of our study was to investigate the added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging i...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Cancer Imaging |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40644-019-0263-z |
id |
doaj-02b34087b434413e8e86c2872c8283b6 |
---|---|
record_format |
Article |
spelling |
doaj-02b34087b434413e8e86c2872c8283b62021-04-02T16:00:15ZengBMCCancer Imaging1470-73302019-11-0119111010.1186/s40644-019-0263-zThe added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinomaDaniel Puhr-Westerheide0Clemens C. Cyran1Josef Sargsyan-Bergmann2Andrei Todica3Franz-Josef Gildehaus4Wolfgang G. Kunz5Robert Stahl6Christine Spitzweg7Jens Ricke8Philipp M. Kazmierczak9Department of Radiology, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichDepartment of Nuclear Medicine, University Hospital, LMU MunichDepartment of Nuclear Medicine, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichDepartment of Neuroradiology, University Hospital, LMU MunichDepartment of Internal Medicine IV, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichDepartment of Radiology, University Hospital, LMU MunichAbstract Background A high proportion of patients with advanced stages of medullary thyroid carcinoma (MTC) present with liver metastasis metastases. The aim of our study was to investigate the added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in MTC. Methods Thirty-six patients (14 female, median age 55 years) with histologically confirmed MTC undergoing gadoxetic acid-enhanced liver MRI within 1 month of matching contrast-enhanced 18F-DOPA-PET/CT between 2010 and 2016 were selected for this IRB-approved retrospective study. 18F-DOPA-PET/CT and multiparametric MRI data sets were read consecutively and liver lesions were categorised on a 5-point Likert scale (1–definitely benign; 2–probably benign; 3–intermediate risk for metastasis; 4–probably metastasis; 5–definitely metastasis). It was noted if gadoxetic acid-enhanced MRI detected additional, 18F-DOPA-PET/CT-occult metastases (category 5) or if gadoxetic acid-enhanced MRI allowed for a definite classification (categories 1 and 5) of lesions for which 18F-DOPA-PET/CT remained inconclusive (categories 2–4). Follow-up PET/CT and MRI examinations were used as a reference standard. Results A total of 207 liver lesions (18F-DOPA-PET/CT 149, MRI 207; 152 metastases, 37 benign cysts, 18 hemangiomas) were analysed. Fifty-eight additional lesions were detected by MRI, of which 54 were metastases (median diameter 0.5 cm [interquartile range 0.4–0.7 cm]) occult on 18F-DOPA-PET/CT. MRI allowed for a definite lesion classification (categories 1 and 5) in 92% (190/207) whereas 18F-DOPA-PET/CT allowed for a definite lesion classification in 76% (113/149). MRI lead to a change in lesion categorisation in 14% (21/149). Conclusion Gadoxetic acid-enhanced MRI allows for a more precise liver staging in MTC patients compared to 18F-DOPA-PET/CT alone, particularly for 18F-DOPA-negative metastases and lesions < 1 cm.http://link.springer.com/article/10.1186/s40644-019-0263-zMagnetic resonance imagingPositron emission tomography computed tomographyNeoplasm metastasisLiverContrast media |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Daniel Puhr-Westerheide Clemens C. Cyran Josef Sargsyan-Bergmann Andrei Todica Franz-Josef Gildehaus Wolfgang G. Kunz Robert Stahl Christine Spitzweg Jens Ricke Philipp M. Kazmierczak |
spellingShingle |
Daniel Puhr-Westerheide Clemens C. Cyran Josef Sargsyan-Bergmann Andrei Todica Franz-Josef Gildehaus Wolfgang G. Kunz Robert Stahl Christine Spitzweg Jens Ricke Philipp M. Kazmierczak The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma Cancer Imaging Magnetic resonance imaging Positron emission tomography computed tomography Neoplasm metastasis Liver Contrast media |
author_facet |
Daniel Puhr-Westerheide Clemens C. Cyran Josef Sargsyan-Bergmann Andrei Todica Franz-Josef Gildehaus Wolfgang G. Kunz Robert Stahl Christine Spitzweg Jens Ricke Philipp M. Kazmierczak |
author_sort |
Daniel Puhr-Westerheide |
title |
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma |
title_short |
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma |
title_full |
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma |
title_fullStr |
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma |
title_full_unstemmed |
The added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in medullary thyroid carcinoma |
title_sort |
added diagnostic value of complementary gadoxetic acid-enhanced mri to 18f-dopa-pet/ct for liver staging in medullary thyroid carcinoma |
publisher |
BMC |
series |
Cancer Imaging |
issn |
1470-7330 |
publishDate |
2019-11-01 |
description |
Abstract Background A high proportion of patients with advanced stages of medullary thyroid carcinoma (MTC) present with liver metastasis metastases. The aim of our study was to investigate the added diagnostic value of complementary gadoxetic acid-enhanced MRI to 18F-DOPA-PET/CT for liver staging in MTC. Methods Thirty-six patients (14 female, median age 55 years) with histologically confirmed MTC undergoing gadoxetic acid-enhanced liver MRI within 1 month of matching contrast-enhanced 18F-DOPA-PET/CT between 2010 and 2016 were selected for this IRB-approved retrospective study. 18F-DOPA-PET/CT and multiparametric MRI data sets were read consecutively and liver lesions were categorised on a 5-point Likert scale (1–definitely benign; 2–probably benign; 3–intermediate risk for metastasis; 4–probably metastasis; 5–definitely metastasis). It was noted if gadoxetic acid-enhanced MRI detected additional, 18F-DOPA-PET/CT-occult metastases (category 5) or if gadoxetic acid-enhanced MRI allowed for a definite classification (categories 1 and 5) of lesions for which 18F-DOPA-PET/CT remained inconclusive (categories 2–4). Follow-up PET/CT and MRI examinations were used as a reference standard. Results A total of 207 liver lesions (18F-DOPA-PET/CT 149, MRI 207; 152 metastases, 37 benign cysts, 18 hemangiomas) were analysed. Fifty-eight additional lesions were detected by MRI, of which 54 were metastases (median diameter 0.5 cm [interquartile range 0.4–0.7 cm]) occult on 18F-DOPA-PET/CT. MRI allowed for a definite lesion classification (categories 1 and 5) in 92% (190/207) whereas 18F-DOPA-PET/CT allowed for a definite lesion classification in 76% (113/149). MRI lead to a change in lesion categorisation in 14% (21/149). Conclusion Gadoxetic acid-enhanced MRI allows for a more precise liver staging in MTC patients compared to 18F-DOPA-PET/CT alone, particularly for 18F-DOPA-negative metastases and lesions < 1 cm. |
topic |
Magnetic resonance imaging Positron emission tomography computed tomography Neoplasm metastasis Liver Contrast media |
url |
http://link.springer.com/article/10.1186/s40644-019-0263-z |
work_keys_str_mv |
AT danielpuhrwesterheide theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT clemensccyran theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT josefsargsyanbergmann theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT andreitodica theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT franzjosefgildehaus theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT wolfganggkunz theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT robertstahl theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT christinespitzweg theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT jensricke theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT philippmkazmierczak theaddeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT danielpuhrwesterheide addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT clemensccyran addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT josefsargsyanbergmann addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT andreitodica addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT franzjosefgildehaus addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT wolfganggkunz addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT robertstahl addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT christinespitzweg addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT jensricke addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma AT philippmkazmierczak addeddiagnosticvalueofcomplementarygadoxeticacidenhancedmrito18fdopapetctforliverstaginginmedullarythyroidcarcinoma |
_version_ |
1721558285837926400 |